ArticleFrontiers in medicine2026
A case report series of influenza A virus-induced pulmonary disease with diverse clinical manifestations.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Influenza A virus (IAV) typically causes influenza-like symptoms; however, in patients with underlying chronic respiratory diseases, it may progress to severe pneumonia and acute respiratory distress syndrome (ARDS). In addition to parenchymal lung injury, some patients may develop severe airway hyperresponsiveness (AHR), including bronchospasm, mucus plug formation, and refractory carbon dioxide retention, often resulting in poor responses to conventional respiratory support. Methods: This study reports three cases of IAV-associated pulmonary disease complicated by respiratory failure. Two patients were elderly men with COPD who presented with refractory AHR and carbon dioxide retention, despite the absence of severe pulmonary infection on imaging. The third patient was a middle-aged man without underlying disease whose chest imaging demonstrated severe pneumonia. All three patients received comprehensive treatment centered on respiratory support, including high-flow oxygen therapy, invasive mechanical ventilation, and individualized antimicrobial therapy; one patient additionally received veno-venous extracorporeal membrane oxygenation (VV-ECMO) support. Results: Despite aggressive treatment, including VV-ECMO support in one patient, the two patients with COPD experienced unfavorable outcomes. Case 1 developed persistent refractory AHR and progressive ventilatory failure, while Case 3 deteriorated in the context of multiple complications. In contrast, the patient without underlying disease, despite severe pneumonia on chest CT, recovered and was discharged following treatment with high-flow nasal oxygen therapy alone. Conclusion: In this case series, the clinical outcomes of IAV-associated pulmonary disease appeared to differ according to underlying pulmonary conditions. Patients with COPD exhibited more persistent AHR and ventilatory failure, whereas the patient without chronic respiratory disease showed reversible airway dysfunction and favorable recovery. These observations suggest that underlying respiratory status may influence the clinical course of IAV-associated AHR; however, further studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.